63659-19-8 Betaxolol hydrochloride AKSci W0012
 
 
Loading Please Wait...
  W0012    AKSci Reference Standard
Betaxolol hydrochloride, 98% (HPLC), powder
 



IDENTITY
CAS Number:63659-19-8
MDL Number:MFCD00242959
MF:C18H30ClNO3
MW:343.89
EINECS:264-384-3
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:114-118°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:H2O: soluble 36mg/mL
Application(s):beta-1 receptors

REVIEW
 Betaxolol hydrochloride is a racemic, selective beta1 receptor blocker used in the treatment of hypertension and glaucoma. It typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2 receptors) as timolol may. Betaxolol also shows greater affininty for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces intraocular pressure by reducing the production of the aqueous humor liquid within the eye. This reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

REFERENCES
[1]Ippolito, Robert Maurice; Vigmond, Stephen Process for the preparation of betaxolol and related 1-[4-[2-(cycloalkylalkoxy)ethyl]phenoxy]-3-(alkylamino)-2-propanol pharmaceuticals Brit. UK Pat. Appl. (1987), GB 2187190 A 19870903.
[2] Ippolito, Robert M.; Vigmond, Stephen Process for preparing phenoxypropanolamines, e.g. betaxolol, via oxazolidine intermediates U.S. (1988), US 4760182 A 19880726.
[3] Bianchetti, G.; Blatrix, C.; Gomeni, R.; Kilborn, J. R.; Larribaud, J.; Luecker, P. W.; Morselli, P. L.; Thebault, J. J.; Trocherie, S. Pharmacokinetics of the new β-adrenoceptor blocker SL 75212 in man after repeated oral administration British Journal of Clinical Pharmacology (1979), 8(4), 408P.
[4] Bianchetti, G.; Blatrix, C.; Gomeni, R.; Kilborn, J. R.; Larribaud, J.; Luecker, P. W.; Thebault, J. J.; Trocherie, S.; Morselli, P. L. Pharmacokinetics of the new β-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration Arzneimittel-Forschung (1980), 30(11), 1912-16.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H302

Precautionary Statements
P264; P270; P301+P312; P330; P501

Current as of December 26, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Beta Blocker


PubChem